Pfizer Inc. today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab ...

Objective To determine whether new users of proton pump inhibitors (PPIs) are at an increased risk of gastric cancer compared with new users of histamine-2 receptor antagonists (H2RAs). Design Using ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...

Avoid co-administration of XOLREMDI and strong CYP3A4 inducers. Reduce XOLREMDI daily dosage when administered with strong CYP3A4 inhibitors. Monitor more frequently for adverse reactions associated ...

The interaction between grapefruit and antidepressants occurs because grapefruit blocks an enzyme called CYP3A4 - found in your small intestine and liver - which metabolises medications.

While the fruit has many benefits, avoid eating it to prevent putting your health at risk if you take the medication ...

The Inspiring Learning Group owned 11 Kingswood camps, with Kingswood having been the largest programme provider for the National Citizen Service. Kingswood, whose history dates to the 1980s and ...

Nurtec ODT (rimegepant) is a brand-name drug prescribed for treating and preventing migraine in adults. Nurtec ODT comes as a tablet that dissolves in your mouth. The dosage can vary depending on ...

In 2022, the FDA approved two new dosage strengths of Caplyta, 10.5 mg and 21 mg for patients concomitantly taking strong or moderate CYP3A4 inhibitors and 21 mg for patients with moderate or ...

Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC. Entered into clinical tr ...